JP2006502112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502112A5 JP2006502112A5 JP2004520114A JP2004520114A JP2006502112A5 JP 2006502112 A5 JP2006502112 A5 JP 2006502112A5 JP 2004520114 A JP2004520114 A JP 2004520114A JP 2004520114 A JP2004520114 A JP 2004520114A JP 2006502112 A5 JP2006502112 A5 JP 2006502112A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- membered
- alkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino, hydroxy Chemical group 0.000 claims 111
- 125000000623 heterocyclic group Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 7
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 7
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 6
- 102100000129 CHURC1 Human genes 0.000 claims 6
- 101710014631 CHURC1 Proteins 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- ZXOFVTMVRJWTAG-UHFFFAOYSA-N N-(1-acetyl-3,3-dimethyl-2H-indol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 ZXOFVTMVRJWTAG-UHFFFAOYSA-N 0.000 claims 2
- BPPJLUFEJJNKCY-UHFFFAOYSA-N N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 BPPJLUFEJJNKCY-UHFFFAOYSA-N 0.000 claims 2
- FNFSNNWULZMNNC-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-[[2-(methylamino)pyrimidin-4-yl]methylamino]benzamide Chemical compound CNC1=NC=CC(CNC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 FNFSNNWULZMNNC-UHFFFAOYSA-N 0.000 claims 2
- HBLHQDSWCAZXOG-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-quinolin-7-yl)-2-(quinazolin-6-ylamino)benzamide Chemical compound N1=CN=CC2=CC(NC3=CC=CC=C3C(=O)NC=3C=C4NCCC(C4=CC=3)(C)C)=CC=C21 HBLHQDSWCAZXOG-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 101700043453 chch-3 Proteins 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 2
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 claims 1
- PYWPWPPRAYOLIB-UHFFFAOYSA-N 1-(3,3-dimethyl-2H-indol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)C)CC(C)(C)C2=C1 PYWPWPPRAYOLIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- HKDKYMLEESDKJH-UHFFFAOYSA-N 1-methyl-4-propylpiperazine Chemical group [CH2+]N1CCN(CC[CH2-])CC1 HKDKYMLEESDKJH-UHFFFAOYSA-N 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- CHXUFRRQOZZSNV-UHFFFAOYSA-N 1-methylpiperidine Chemical group [CH2]N1CCCCC1 CHXUFRRQOZZSNV-UHFFFAOYSA-N 0.000 claims 1
- OIPPARMLEWQGSK-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-N-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=C(F)C=C1 OIPPARMLEWQGSK-UHFFFAOYSA-N 0.000 claims 1
- IKDAWKWPRPYNJA-UHFFFAOYSA-N 2-[1-(2-aminopyrimidin-4-yl)ethylamino]-N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)benzamide Chemical compound C=1C=CC=C(C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)C=1NC(C)C1=CC=NC(N)=N1 IKDAWKWPRPYNJA-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- VBZWSGALLODQNC-UHFFFAOYSA-N Hexafluoroacetone Chemical group FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims 1
- COZSLNKBURQTJX-UHFFFAOYSA-N N-(1-acetyl-3,3-dimethyl-2H-indol-6-yl)-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC3=CC=C4C(C)(C)CN(C4=C3)C(=O)C)=CC=NC2=C1 COZSLNKBURQTJX-UHFFFAOYSA-N 0.000 claims 1
- IKTFEBNTUYTPCK-UHFFFAOYSA-N N-(1-ethyl-3,3-dimethyl-2H-indol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C2N(CC)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 IKTFEBNTUYTPCK-UHFFFAOYSA-N 0.000 claims 1
- YYVHACOWHFZZJT-UHFFFAOYSA-N N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC=3C=C4NCC(C4=CC=3)(C)C)=CC=NC2=C1 YYVHACOWHFZZJT-UHFFFAOYSA-N 0.000 claims 1
- QLFQMDKFOJZHBK-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-(pyridazin-4-ylmethylamino)benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=NN=C1 QLFQMDKFOJZHBK-UHFFFAOYSA-N 0.000 claims 1
- JQVREGRYMBTPRO-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 JQVREGRYMBTPRO-UHFFFAOYSA-N 0.000 claims 1
- FTNKCGULGWHQPV-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-[(4-fluorophenyl)methylamino]benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=C(F)C=C1 FTNKCGULGWHQPV-UHFFFAOYSA-N 0.000 claims 1
- GUIOOGNPPDHMRU-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-[1-[2-(methylamino)pyrimidin-4-yl]ethylamino]benzamide Chemical compound CNC1=NC=CC(C(C)NC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 GUIOOGNPPDHMRU-UHFFFAOYSA-N 0.000 claims 1
- GUIOOGNPPDHMRU-MRXNPFEDSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-[[(1R)-1-[2-(methylamino)pyrimidin-4-yl]ethyl]amino]benzamide Chemical compound CNC1=NC=CC([C@@H](C)NC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 GUIOOGNPPDHMRU-MRXNPFEDSA-N 0.000 claims 1
- SKHDQKQGFCSJDS-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-2-fluoro-6-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=C(F)C=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 SKHDQKQGFCSJDS-UHFFFAOYSA-N 0.000 claims 1
- YAWXEPJVBFFVAI-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-3-fluoro-2-[(4-fluorophenyl)methylamino]benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC(F)=C1NCC1=CC=C(F)C=C1 YAWXEPJVBFFVAI-UHFFFAOYSA-N 0.000 claims 1
- SHNBMTHPUCMPQC-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-4-fluoro-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=C(F)C=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 SHNBMTHPUCMPQC-UHFFFAOYSA-N 0.000 claims 1
- FBSYURCCDOMSHX-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-5-fluoro-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC(F)=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 FBSYURCCDOMSHX-UHFFFAOYSA-N 0.000 claims 1
- JQUISUUSKKADNO-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)-6-fluoro-6-[(4-fluorophenyl)methylamino]cyclohexa-2,4-diene-1-carboxamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1C=CC=CC1(F)NCC1=CC=C(F)C=C1 JQUISUUSKKADNO-UHFFFAOYSA-N 0.000 claims 1
- YHNUIHYDPTVZRY-UHFFFAOYSA-N N-(4,4-dimethyl-2,3-dihydro-1H-quinolin-7-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC=3C=C4NCCC(C4=CC=3)(C)C)=CNC2=N1 YHNUIHYDPTVZRY-UHFFFAOYSA-N 0.000 claims 1
- YTITUUIWIKQKDQ-UHFFFAOYSA-N N-(4-tert-butylphenyl)-2-(isoquinolin-7-ylamino)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CC=C1NC1=CC=C(C=CN=C2)C2=C1 YTITUUIWIKQKDQ-UHFFFAOYSA-N 0.000 claims 1
- MXMQURVEDWCCER-UHFFFAOYSA-N N-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 MXMQURVEDWCCER-UHFFFAOYSA-N 0.000 claims 1
- HAZZWCMIYVZRGW-UHFFFAOYSA-N N-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC2=CC=CC=C12 HAZZWCMIYVZRGW-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- WHXUCURNHXAEAU-UHFFFAOYSA-N ethenyl(prop-1-en-2-yl)azanide Chemical group [CH2+]C(=C)[N-]C=C WHXUCURNHXAEAU-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39514402P | 2002-07-09 | 2002-07-09 | |
| US10/615,809 US7307088B2 (en) | 2002-07-09 | 2003-07-08 | Substituted anthranilic amide derivatives and methods of use |
| PCT/US2003/021601 WO2004005279A2 (en) | 2002-07-09 | 2003-07-09 | Substituted anthranilic amide derivatives and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502112A JP2006502112A (ja) | 2006-01-19 |
| JP2006502112A5 true JP2006502112A5 (US07816364-20101019-C00082.png) | 2006-08-24 |
Family
ID=30118477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004520114A Pending JP2006502112A (ja) | 2002-07-09 | 2003-07-09 | 置換アントラニルアミド誘導体および使用方法 |
Country Status (8)
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| TW201319088A (zh) | 2003-07-18 | 2013-05-16 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
| US20050130986A1 (en) * | 2003-11-21 | 2005-06-16 | Eklund Kari K. | Treatment of spondylarthropathies |
| US7507748B2 (en) * | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| US7906511B2 (en) | 2005-03-31 | 2011-03-15 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having pyrimidinylalkylthio group |
| JP4834441B2 (ja) * | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | ピリミジニルアルキルチオ基を有する新規環式化合物 |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| CA2629964A1 (en) * | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007092178A1 (en) | 2006-02-10 | 2007-08-16 | Amgen Inc. | Hydrate forms of amg706 |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008086014A2 (en) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| WO2009051244A1 (ja) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
| CA2746386A1 (en) * | 2008-12-19 | 2010-06-24 | Amgen Inc. | Improved method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole |
| CN102448920B (zh) * | 2009-03-25 | 2016-04-06 | Abbvie公司 | 抗病毒化合物和其用途 |
| WO2010119992A1 (en) * | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| ES2620521T3 (es) | 2011-03-23 | 2017-06-28 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| JP6840666B2 (ja) | 2014-10-03 | 2021-03-10 | マヘーシュワリ, ディヴィヤMAHESHWARI, Divya | 新規なアントラニル酸誘導体 |
| WO2016112111A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| MX2017011269A (es) | 2015-03-06 | 2018-01-12 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. |
| JP6800872B2 (ja) | 2015-03-06 | 2020-12-16 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤とその使用 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| JP7079772B2 (ja) | 2016-09-07 | 2022-06-02 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤の結晶形態および製造方法 |
| MY196830A (en) | 2016-12-22 | 2023-05-03 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| AR110963A1 (es) * | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US11446279B2 (en) | 2017-06-29 | 2022-09-20 | The Regents Of The University Of California | Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof |
| CN109422655B (zh) * | 2017-08-24 | 2021-10-29 | 中国石油化工股份有限公司 | 一种苯酚直接氨化制苯胺的方法 |
| EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20220002311A1 (en) | 2018-12-20 | 2022-01-06 | Amgen Inc. | Kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| CR20210387A (es) | 2018-12-20 | 2021-08-19 | Amgen Inc | Inhibidores de kif18a |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CN118834208A (zh) | 2019-05-21 | 2024-10-25 | 美国安进公司 | 固态形式 |
| AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| CA3147276A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CA3146693A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
| MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
| KR20220101125A (ko) | 2019-11-14 | 2022-07-19 | 암젠 인크 | Kras g12c 억제제 화합물의 개선된 합성 |
| CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ｒａｓ阻害剤としてのインドール誘導体 |
| CN116134017A (zh) * | 2020-09-24 | 2023-05-16 | 贝达药业股份有限公司 | 双环化合物及其应用 |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| JP2024517847A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| EP4448526A1 (en) | 2021-12-17 | 2024-10-23 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH438343A (de) * | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
| US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
| US3822277A (en) * | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
| US3452019A (en) * | 1967-11-16 | 1969-06-24 | Wallace & Tiernan Inc | 1-phenylalkyl-tetrahydro-halo-sulfamyl-quinazolinone |
| US3557111A (en) * | 1968-03-29 | 1971-01-19 | Bola Vithal Shetty | N and n,n-alkyl,acyl and arylsulfamyl-tetrahydroquinazolinones |
| US3567746A (en) * | 1968-07-10 | 1971-03-02 | Pennwalt Corp | N-aryl benzamides |
| BE794226A (fr) * | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
| GB1474296A (en) | 1975-01-23 | 1977-05-18 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| GB1573186A (en) * | 1977-09-14 | 1980-08-20 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH0233030B2 (ja) | 1982-01-18 | 1990-07-25 | Mitsui Toatsu Chemicals | Surufuamoiruansokukosanjudotaioyobisoreojukoseibuntoshitefukumuchiryoyososeibutsu |
| FR2540870A1 (fr) * | 1983-02-15 | 1984-08-17 | Provesan Sa | Nouveaux derives de betaines n-iminopyridinium, leur preparation et leur application en tant que medicaments |
| SU1156362A1 (ru) | 1983-02-17 | 1991-07-30 | Пермский государственный фармацевтический институт | Ариламиды П-(2 @ ,4 @ )- или (3 @ ,4 @ )-диметоксибензилантраниловых кислот как промежуточные вещества дл синтеза биологически активных перхлоратов 1-[(2 @ ,4 @ ) или (3 @ ,4 @ )-диметоксибензил]-2-метил-3-арил-4-(3Н)-хиназолинони |
| DE3305755A1 (de) * | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
| ES2058656T3 (es) | 1989-04-20 | 1994-11-01 | Boehringer Ingelheim Pharma | 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida. |
| DE69007891T2 (de) | 1989-06-28 | 1994-08-25 | Boehringer Ingelheim Pharma | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one und -thione und ihre Verwendung bei der AIDS-Vorbeugung oder -Behandlung. |
| CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
| US5571912A (en) * | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5532358A (en) * | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| US5770613A (en) * | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| ID22781A (id) | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan nikotinamida |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| JP2002512633A (ja) * | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
| ATE297203T1 (de) * | 1997-06-26 | 2005-06-15 | Lilly Co Eli | Antithrombotische mitteln |
| IL133625A0 (en) * | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
| US6313151B1 (en) * | 1997-06-26 | 2001-11-06 | Eli Lilly And Company | Antithrombotic agents |
| US6140351A (en) * | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| RU2226529C2 (ru) | 1997-12-19 | 2004-04-10 | Шеринг Акциенгезельшафт | Производные ортоантраниламида в качестве антикоагулянтов, фармацевтическая композиция и способ лечения |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| JP2002516909A (ja) | 1998-06-05 | 2002-06-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用 |
| KR100720844B1 (ko) | 1998-07-08 | 2007-05-25 | 사노피-아벤티스 도이칠란트 게엠베하 | 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제 |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| ATE326453T1 (de) | 1998-12-23 | 2006-06-15 | Lilly Co Eli | Antithrombotische amide |
| JP2002533454A (ja) * | 1998-12-23 | 2002-10-08 | イーライ・リリー・アンド・カンパニー | 芳香族アミド類 |
| CA2358095A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor xa |
| JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| DE19941540C2 (de) | 1999-09-01 | 2002-08-29 | Aventis Pharma Gmbh | Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| AU2001231143A1 (en) | 2000-01-27 | 2001-08-07 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| DE60115394T2 (de) | 2000-02-29 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | Benzamide und ähnliche inhibitoren vom faktor xa |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| US6934248B1 (en) | 2000-07-20 | 2005-08-23 | Nortel Networks Limited | Apparatus and method for optical communication protection |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| EP1394154A4 (en) * | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
| US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| JP2004528378A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | Ｎ−オキシドアントラニルアミド誘導体と医薬製剤としての利用 |
| DE10125295A1 (de) | 2001-05-15 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
| DE50206476D1 (de) * | 2001-05-08 | 2006-05-24 | Schering Ag | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
| KR20030094395A (ko) | 2001-05-08 | 2003-12-11 | 쉐링 악티엔게젤샤프트 | Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3의 억제제로서의 선택적안트라닐아미드 피리딘 아미드 |
| GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| GB0126901D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| RS70104A (en) | 2002-02-11 | 2007-02-05 | Pfizer Limited, | Nicotinamide derivatives useful as pde4 inhibitors |
| GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US7517894B2 (en) * | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2003
- 2003-07-08 US US10/615,809 patent/US7307088B2/en not_active Expired - Lifetime
- 2003-07-09 PL PL03375586A patent/PL375586A1/xx unknown
- 2003-07-09 WO PCT/US2003/021601 patent/WO2004005279A2/en active IP Right Grant
- 2003-07-09 CA CA002489166A patent/CA2489166A1/en not_active Abandoned
- 2003-07-09 MX MXPA05000120A patent/MXPA05000120A/es not_active Application Discontinuation
- 2003-07-09 JP JP2004520114A patent/JP2006502112A/ja active Pending
- 2003-07-09 EP EP03763451A patent/EP1519921A2/en not_active Withdrawn
- 2003-07-09 AU AU2003256481A patent/AU2003256481B2/en not_active Ceased
